A company backed by global private investment firm Permira has made a significant investment in PharmaCord, a provider of patient services for the pharmaceutical industry, which will continue to be led by founder and CEO Nitin Sahney.
Both Sahney and the existing management team will also remain as significant investors in the business, although financial terms of the transaction have not been disclosed.
According to a press statement, PharmaCord “serves as a commercialisation partner for life sciences organisations providing a comprehensive range of solutions aimed at support the patient journey for specialty medications through a range of services that raise awareness, facilitate access to treatment, improve affordability and promote therapy adherence”.
The deal, which is subject to customary regulatory approvals, is expected to close by Q4 2024.
Centerview Partners and Willkie Farr & Gallagher advised PharmaCord. Jefferies, Leerink Partners and Skadden, Arps, Slate, Meagher & Flom advised Permira.
